Azacitidine Is Effective in Patients with Low Intermediate-1 Risk Myelodysplastic Syndrome Managed in Community Based Practice: Preliminary Data From the Spanish Compassionate Use Registry

被引：0
|
作者：
Garcia, Regina [1 ]
de Miguel, Dunia [2 ]
Bernal, Maria-Teresa [3 ]
Tormo, Mar [4 ]
Sanz, Guillermo [5 ]
de Paz, Raquel [6 ]
Figueredo, Antonio [7 ]
Amutio, Maria E. [8 ]
Guzman, Jose L. [9 ]
机构：
[1] Hosp Virgen Victoria, Malaga, Spain
[2] Hosp Univ Guadalaja, Madrid, Spain
[3] PETHEMA Grp, Oviedo, Spain
[4] Hosp Clin, Valencia, Spain
[5] Hosp Univ La Fe, Valencia, Spain
[6] Hosp Univ La Paz, Madrid, Spain
[7] Hosp Virgen Macarena, Seville, Spain
[8] Hosp Cruces, Bilbao, Spain
[9] Hosp SAS Jerez de la Frontera, Jerez de la Frontera, Spain
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1462 / 1462
页数：1
相关论文
共 50 条
  • [1] Different Clinical Results with the Use of Different Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndrome Managed in Community-Based Practice: Effectiveness and Safety Data From the Spanish Azacitidine Compassionate Use Registry.
    Garcia, Regina
    de Miguel, Dunia
    Bailen, Alicia
    Ramon Gonzalez, Jose
    Sanz, Guillermo
    Falantes, Jose F.
    Andreu, Rafael
    Tormo, Mar
    Duarte, Rafael F.
    Figueredo, Antonio
    BLOOD, 2009, 114 (22) : 1084 - 1085
  • [2] OUTCOMES OF CONTINUED AZACITIDINE TREATMENT FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME IN IPSS LOW AND INTERMEDIATE-1
    Moon, J. H.
    Sohn, S. K.
    Cho, Y. Y.
    Kim, Y. K.
    Kim, H. J.
    Kim, M. K.
    Do, Y. R.
    Song, M. K.
    Lee, W. K.
    Lee, S. M.
    Kim, H.
    Won, J. H.
    Yeon, J. Deok
    HAEMATOLOGICA, 2012, 97 : 141 - 141
  • [3] Cytogenetic Evolution in Patients with IPSS Low and Intermediate-1 Risk. Study from the Spanish Group of Myelodysplastic Syndrome
    Marcel Merchan, Brayan
    Ortega, Margarita
    Jose Llamas-Poyato, Mara
    Cortes, Montserrat
    Arnan, Montserrat
    Cervero, Carlos
    Montoro, Julia
    Gimenez, Teresa
    Lopez, Mara
    Arenillas, Leonor
    Valcarcel, David
    BLOOD, 2014, 124 (21)
  • [4] Effectiveness of Various Dosage Regimens of Azacitidine In Patients with Myelodysplastic Syndromes: Safety and Efficacy Final Data From the Spanish Azacitidine Compassionate Use Registry
    Garcia, Regina
    De Miguel, Dunia
    Bargay, Joan
    Bernal, Teresa
    Ramon Gonzalez, Jose
    Tormo, Mar
    Ramos, Fernando
    Lapiedra, Andreu
    Falantes, Jose
    Xicoy, Blanca
    Sanz, Guillermo F.
    Mondedeu, Benet
    Brunet, Salut
    Sanchez, Joaquin
    BLOOD, 2010, 116 (21) : 772 - 772
  • [5] TREATMENT WITH AZACITIDINE IN THERAPY-INDUCED MSD. PRELIMINARY DATA FROM THE SPANISH AZACITIDINE COMPASSIONATE USE REGISTRY
    Garcia, R.
    Entrena, L.
    Sanz, G.
    De Miguel, M. D.
    Amutio, M.
    Bernal, T.
    Besalduch, J.
    Brunet, S.
    Bailen, A.
    Guzman, J.
    Sanchez, J.
    Martinez, C.
    Garcia-Quiroga, H.
    Garcia-Talavera, M.
    Falantes, J.
    Garrido, R.
    Romero, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 560 - 560
  • [6] Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome
    Chien, Kelly S.
    Kim, Kunhwa
    Nogueras-Gonzalez, Graciela M.
    Borthakur, Gautam
    Naqvi, Kiran
    Daver, Naval G.
    Montalban-Bravo, Guillermo
    Cortes, Jorge E.
    DiNardo, Courtney D.
    Jabbour, Elias
    Alvarado, Yesid
    Andreeff, Michael
    Bose, Prithviraj
    Jain, Nitin
    Kadia, Tapan M.
    Huang, Xuelin
    Sheppard, Kimberly B.
    Klingner-Winton, Cheri
    Pierce, Sherry A.
    Dong, Xiao Qin
    Soltysiak, Kelly A.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 195 (03) : 378 - 387
  • [7] ACQUISITION OF CYTOGENETIC ABNORMALITIES IN PATIENTS WITH IPSS LOW AND INTERMEDIATE-1 RISK. STUDY FROM THE SPANISH GROUP OF MYELODYSPLASTIC SYNDROME
    Merchan, B.
    Ortega, M.
    Llamas-Poyato, M. J.
    Cortes, M.
    Arnan, M.
    Cervero, C.
    Montoro, J.
    Gimenez, T.
    Lopez, M.
    Arenillas, L.
    Valcarcel, D.
    LEUKEMIA RESEARCH, 2015, 39 : S136 - S136
  • [8] EXPERIENCE WITH THE USE OF 5-AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME OF LOW/INTERMEDIATE RISK
    Llorente Dunia, De Miguel
    Lopez Nuria, Golbano
    Morfa Miguel, Diaz
    Juanis Jaime, Arbeteta
    Sanz Dolores, Morales
    Perez Dolores, Subira
    Maqueda Cristina, Fernandez
    Ramo Alejandro, Vazquez
    Martin Sonia, Herrero
    Albiz Blanca, Pinedo
    HAEMATOLOGICA, 2016, 101 : 152 - 152
  • [9] Clinical and Biological Characterization of Patients with Low/Intermediate-1 Risk Myelodysplastic Syndrome and Iron Overload
    Ivars, David
    Collado, Rosa
    Alguero, Carmen
    Carmen Tormos, M.
    Diaz, Laura
    Luis Garcia-Ghnenez, Jose
    Arrizabalaga, Beatriz
    Orero, Mayte
    Perez, Pedro
    Sanchez, Magdalena
    Angeles Ruiz, M.
    Yaguee, Nuria
    Sancho-Tello, Reyes
    Regadera, Ana
    Tormo, Mar
    Egea, Mercedes
    Vidal, Elena
    Enrique O'Connor, J.
    Saez, Guillermo T.
    Carbonell, Felix
    BLOOD, 2012, 120 (21)
  • [10] Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study
    Valcarcel, David
    Sanz, Guillermo
    Ortega, Margarita
    Nomdedeu, Benet
    Luno, Elisa
    Diez-Campelo, Maria
    Teresa Ardanaz, Maria
    Pedro, Carmen
    Montoro, Julia
    Collado, Rosa
    Andreu, Rafa
    Marco, Victor
    Teresa Cedena, Maria
    de Paz, Raquel
    Tormo, Mar
    Xicoy, Blanca
    Ramos, Fernando
    Bargay, Joan
    Gonzalez, Bernardo
    Brunet, Salut
    Antonio Munoz, Juan
    Gomez, Valle
    Bailen, Alicia
    Sanchez, Joaquin
    Merchan, Brayan
    del Canizo, Consuelo
    Vallespi, Teresa
    LANCET HAEMATOLOGY, 2015, 2 (06): : E260 - E266
12345